In the present study, our formulation of curcumin nanoparticles was tested as co-treatment with cisplatin in a rat ovarian cancer model, with a focus on PI3K/Akt and JAK/STAT3 pathways. The gene discussed is AKT1; the disease is ovarian carcinoma.